To initiate or not to initiate antiretroviral therapy in the critically ill?
Keywords:
initiate, antiretroviral therapy, ART, critically ill, AIDS, HIVAbstract
The use of highly active antiretroviral therapy (HAART) in people infected with the human immunodeficiency virus (HIV) has resulted in a significant increase in life expectancy since the roll-out programmes were initiated in 1996.1 Increased life expectancy has resulted in increasing optimism and the aggressive management of these patients. Thus, admissions to the intensive care unit (ICU) are increasing, with better outcomes than those achieved in the pre-antiretroviral therapy (ART) era.2 Although, the reasons for critical illness have shifted from acquired immune deficiency syndrome (AIDS)-related opportunistic infections to chronic non-AIDS co-morbidities, opportunistic infections still contribute significantly to the HIV-related ICU morbidity burden in developing countries.3Downloads
Issue
Section
SASA Main Conference Texts
License
By submitting manuscripts to SAJAA, authors of original articles are assigning copyright to the SA Society of Anaesthesiologists. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJAA for educational and research purposes without obtaining permission.
The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License. The SAJAA does not hold itself responsible for statements made by the authors.